InvestorsHub Logo
Followers 26
Posts 4429
Boards Moderated 0
Alias Born 06/08/2010

Re: nyctraydr post# 71146

Friday, 02/05/2016 10:14:47 AM

Friday, February 05, 2016 10:14:47 AM

Post# of 80490
The legacy crowd here remembers the Ariad Investor/poster "biotechedge", aka BTH, who when we were all so bullish, he would complain that the stock 'couldn't hold a gain'. (I cleaned that up!)

BTH sold at $13, and bought a ranch somewhere. He was not overly swayed by the scientific and company PRs that came out, sold a what we thought was a bad price, and moved on. He looks smart now.

As to the article posted yesterday, glass posted this yesterday (edited by me for compliance to TOU):

The author of "Here’s Why Ariad Could Be a Top Oncology Pick for 2016" notes toward the end that he foresees a number of positive catalysts for ARIA in 2016, prefaced with the qualifier "if everything goes smoothly."

However, I would note that we -- especially the pre-crater crowd -- are well aware of how major a hurdle this is, as almost every step at Ariad is a stumble (like with Briga: slow getting trial started, clung to EGFR idea, insisted on heavy dose and killed a dude, re-vamped trial process took ages...).

So it's fine to be optimistic if we have managed to fall up the stairs and are pretty much at the finish line. But there are any number of pitfalls that we could hit still.

So my reaction is to look askance at the analysis.



Point being, it is easy to run wild with the possibilities that Ariad could present. History tells us, walking is probably a better way to go.

The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.